Pharmaceutical Executive has an outstanding feature titled “Regional Trends in Bioinnovation Investment” that examines how the Big3Bio regions of San Francisco Bay Area and Boston/Cambridge become successful biocluster hubs and “identify the necessary foundations for a strong biotech ecosystem”:
“Bioinnovation has been a key driver of US economic development, with notable examples of success in California’s Bay Area and the Boston/Cambridge nexus in Massachusetts. Over the past two decades, hundreds of thousands of jobs have been created through start-up companies and the large multinational anchor companies that attract ancillary support services, including venture capital. Today, many other jurisdictions—both in the United States and abroad—are seeking to replicate this productive ecosystem to support their own economic growth.”
Though the report mostly concentrates on “The Cambridge Model” and developments in that area, it also offers details on how other regions, like Philadelphia, can learn from that example.
The two authors of the report were Amanda Christini, MD, Director of Strategic Initiatives at Penn Medicine Center for Healthcare Innovation, and Ken Kaitin, Professor and Director of the Tufts Center for the Study of Drug Development, Tufts University School of Medicine.